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The development of antiretroviral therapy (ART) for the
treatment of human immunodeficiency virus (HIV) infection
represents one of the greatest achievements of modern
medicine. ART has significantly changed the clinical outcome of
HIV-infected individuals, the rates of HIV-related mortality/
morbidity and the nature/transmission of HIV-1 infection in
countries with access to antiretroviral drugs [1].
It is now evident, however, that this approach cannot
rapidly lead to a cure for HIV infection. Indeed, the virus may
still persist in specific reservoirs even in treated patients in
whom viraemia is well controlled [2,3]. More intriguingly, the
fact that treated patients may present a residual immune
dysregulation associated with chronic immune activation [4]
makes HIV eradication an aspirational goal. In addition to
causing uncertainty, this has led us to consider the topic of HIV
eradication with some scepticism.
All these considerations, alongside issues of compliance,
drug access and toxicity linked to chronic therapy, highlight the
need to implement different and innovative strategies in the
field of HIV eradication. In other words, together with an
extensive approach to the issue from a traditional scheme-
driven point of view, we need to continue to investigate HIV
eradication from a completely new and ground-breaking
standpoint. One possibility is to extrapolate and apply to the
HIV field findings and knowledge from areas only potentially
related to the HIV issue.
In this context, the paper by Didier Raoult’s group published
in this issue of CMI [5] represents an interesting and challenging
approach to the topic. It is a radical change resulting from the
use of advanced molecular techniques. The authors speculate
that the persistence of HIV-DNA in the host genome should no
longer be considered an obstacle to HIV eradication but,
rather, the beginning of a process of HIV endogenization that
may ultimately lead to eradication of HIV infection from the
human species.
Starting from the fact that the characterization of ‘HIV elite
controller’ status (i.e. subjects achieving long-term control of
viraemia without highly active antiretroviral therapy [6,7]) has
not yet been elucidated, the study monitored two HIV-in-
fected patients (one subject for more than 10 years) with no
HIV-related disease and no detection of plasma HIV RNA or
cell-associated HIV DNA with routine tests. Both subjects
were infected at different times and in different ways and are
immunologically reactive against HIV proteins (indicating that
they were actually infected). However, their PBMCs harbour
very few copies of integrated HIV-DNA (detected only when
new molecular techniques are used) that are not replica-
tion-competent, probably due to the high content of tran-
scription stop signals. The authors assumed that APOBEC3G,
a well-known cytosine deaminase that can be encapsidated and
may subsequently hypermutate the neosynthetized cDNA
inside the virion during reverse transcription, might be
functionally involved in inducing such high defectivity in the
HIV genome.
The literature on the acquisition of retroviruses in the
human genome is plentiful but, so far, few attempts have been
made to frame this knowledge in the field of HIV. Indeed, we
know that human chromosomes contain a huge number of
retroviral sequences (they account for about 8% of our
genome) [8,9]. Once inserted into the human genome none of
these retroviral sequences remain static as they have suffered
from post-insertion mutations (including insertion of tran-
scription stop signals), deletions and recombinations that have
stopped them being infectious. At least some of the above
modifications are known to be driven by the action of now
well-known cellular restriction antiretroviral factors, of which
the APOBEC-superfamily is one of the most prominent [10]. It
is assumed that the origin of such retroviral sequences and the
related process of endogenization (the process entailing a
germline integration that ultimately allows vertical transfer and
functional attenuation of the provirus) are derived from
exogenous retroviruses that circulated millions of years ago.
However, although we do not have any demonstration in
humans, it is no longer true that this phenomenon occurred
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only millions of years ago. In 2006 two papers demonstrated
an endogenization process in Koala retrovirus (KoRV) intro-
duced into koala bears only a century ago [11,12]. Functional
assessment of specific sequences contributing to KoRV’s
attenuation from KoRV’s closest genomic relative, the highly
infectious exogenous gibbon ape leukaemia virus (GALV)-like
progenitor virus, has allowed the identification of specific
modifications in the KoRV genome that correlate with its
endogenization [13]. This phenomenon is still under scrutiny
to find the evolutionary advantage of the virus undergoing such
a process. The model may hopefully provide interesting
findings to support the fascinating speculation provided in
the paper by Raoult’s group paper on the role, if any, of viral
endogenization in the eradication of HIV infection.
Several caveats must be taken into account when reading
the study of Raoult’s group [5].
First, the study examined only two subjects. Therefore,
before fully considering the data we have to wait for studies
involving substantially larger numbers of subjects (that include
for instance ‘elite controller’ cohorts).
Second, in this paper the association between APOBEC3G
and induction of defectivity in the HIV genome in the two
subjects is only speculative and, before reaching any conclusion
on the issue, other cellular restriction factors, acting in
different ways and causing other types of inactivation, should
be considered. Moreover, the presence of defective HIV
proviral genomes in cellular DNA from patients in various
clinical conditions has been described, due to a number of
mechanisms, including deletions and APOBEC3-induced edit-
ing [14].
Third, the clinical relevance, if any, of the current obser-
vations needs to be further elucidated, given that the
endogenization process does not necessarily mean inactivation
of the HIV genome. Studies are in progress to exploit the
potential pathogenetic role of human endogenous retrovirus
(HERV) sequences and their possible association with disease,
particularly tumorigenesis [15,16].
Nevertheless, new avenues of research are being explored
in our understanding of HIV-host interactions and pathogen-
esis. These new findings, together with the related specula-
tions, may be further exploited in the search for new HIV-1
cure strategies.
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